Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Bristol-Myers Squibb swallows last of antibody pioneers

Nature Biotechnology volume 27, pages 781–783 (2009)Cite this article

The price for Medarex was steep at $2.4 billion, but BMS, headquartered in New York, sees Princeton, New Jersey–based neighbor Medarex as playing a big part in its 'string of pearls' strategy. With a swathe of patent expirations heading its way up through 2014, BMS has been intent on damage control, setting the stage to become “a next-generation biopharmaceutical company,” says Brian Henry, the company's director of business communications. As part of its strategy, BMS divested its wound care and medical imaging divisions, and spun off Mead Johnson Nutritionals.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Acton, Massachusetts

    Malorye Allison

Authors
  1. Malorye Allison
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Allison, M. Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol 27, 781–783 (2009). https://doi.org/10.1038/nbt0909-781

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0909-781

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing